ELISA/assay

Rat Bone Morphogenetic Protein Receptor 1A ELISA Kit

MBS720872

48-Strip-Wells

470 USD

ELISA Kit

Rat Bone Morphogenetic Protein Receptor 1A ELISA Kit

Bone Morphogenetic Protein Receptor 1A

bone morphogenetic protein receptor type-1A; Bone morphogenetic protein receptor type-1A; bone morphogenetic protein receptor type-1A; ALK-3; BMPR-1A; BMP type-1A receptor; activin receptor-like kinase 3; activin A receptor, type II-like kinase 3; serine/threonine-protein kinase receptor R5; bone morphogenetic protein receptor, type IA; Activin receptor-like kinase 3; ALK-3; Serine/threonine-protein kinase receptor R5; SKR5; CD_antigen: CD292

BMPR1A

BMPR1A; BMPR1A; ALK3; SKR5; CD292; ACVRLK3; 10q23del; ACVRLK3; ALK3; BMP type-1A receptor; BMPR-1A; ALK-3; SKR5

BMR1A_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of BMPR1A. No significant cross-reactivity or interference between BMPR1A and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between BMPR1A and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This BMPR1A ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat BMPR1A. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Signal Transduction

Principle of the assay: BMPR1A ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-BMPR1A antibody and an BMPR1A-HRP conjugate. The assay sample and buffer are incubated together with BMPR1A-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the BMPR1A concentration since BMPR1A from samples and BMPR1A-HRP conjugate compete for the anti-BMPR1A antibody binding site. Since the number of sites is limited, as more sites are occupied by BMPR1A from the sample, fewer sites are left to bind BMPR1A-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The BMPR1A concentration in each sample is interpolated from this standard curve.

41349437

NP_004320.2

NM_004329.2

60,198 Da

BMP Signalling And Regulation Pathway (198910); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Endochondral Ossification Pathway (198812); Heart Development Pathway (198802); Hippo Signaling Pathway (749777); Hippo Signaling Pathway (750388); Integrated Breast Cancer Pathway (219801); Signal Transduction Pathway (477114); Signaling By BMP Pathway (106336)

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008]

BMPR1A: a serine/threonine-protein kinase receptor for Bone morphogenetic protein-2 and -4 (BMP-2 and BMP-4). Defects in BMPR1A are a cause of juvenile polyposis syndrome (JPS) and Cowden disease (CD), a cancer syndrome characterized by multiple hamartomas and by a high risk for breast, thyroid and endometriel cancers. Protein type: Membrane protein, integral; Kinase, protein; Protein kinase, TKL; Protein kinase, Ser/Thr (receptor); EC 2.7.11.30; TKL group; STKR family; Type1 subfamily. Chromosomal Location of Human Ortholog: 10q22.3. Cellular Component: cell soma; dendrite; plasma membrane; integral to membrane; caveola. Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; protein homodimerization activity; metal ion binding; SMAD binding; transmembrane receptor protein serine/threonine kinase activity; ATP binding; receptor signaling protein serine/threonine kinase activity. Biological Process: neural plate mediolateral pattern formation; transcription from RNA polymerase II promoter; hindlimb morphogenesis; developmental growth; neural crest cell development; positive regulation of transcription, DNA-dependent; mesendoderm development; paraxial mesoderm structural organization; dorsal/ventral axis specification; palate development; protein amino acid phosphorylation; negative regulation of neurogenesis; BMP signaling pathway; transforming growth factor beta receptor signaling pathway; positive regulation of mesenchymal cell proliferation; ectoderm development; Mullerian duct regression; somitogenesis; in utero embryonic development; stem cell maintenance; lateral mesoderm development; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; positive regulation of osteoblast differentiation; mesoderm formation; pituitary gland development; cartilage development; embryonic organ development; immune response; embryonic digit morphogenesis; positive regulation of epithelial cell proliferation; regulation of lateral mesodermal cell fate specification; lung development. Disease: Juvenile Polyposis Syndrome; Polyposis Syndrome, Hereditary Mixed, 2

48-Strip-Wells

470 USD

96-Strip-Wells

675